Navigation Links
Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Date:12/3/2008

EMERYVILLE, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced that the FDA has reviewed the company's manufacturing and control process descriptions (CMC), and has provided guidance on how Bionovo can move forward with the development of Menerba (formerly named MF101) for menopausal hot flashes.

"We have concluded three CMC discussions with the FDA, and are moving to address the Agency's recommendations for further development of Menerba. The recommendations with respect to the analytical characterization were made by the Pre-Marketing division of the Agency, in order to ensure continuous drug consistency. There are some areas of the drug development process requiring further discussion on how to best implement the Agency's Guidance for Industry for Botanical Drug Products. Bionovo will be moving with all possible diligence to reach agreement on these areas with the FDA. We will start manufacturing the clinical material using the commercial process immediately. During these discussions no concerns were expressed about either the safety nor the efficacy of Menerba," said Dr. Isaac Cohen, Bionovo's Chairman and CEO.

Bionovo completed a multicenter Phase 2, double-blind, placebo-controlled randomized clinical trial evaluating Menerba for the treatment of hot flashes in 217 healthy post-menopausal women enrolled at 6 clinical sites in the U.S. The principal investigator of the trial was Dr. Deborah Grady from the University of California, San Francisco. Menerba showed a statistically significant reduction in the number of hot flashes after 12 weeks of treatment (-62%, p=0.05) and had a statistically significant reduction in nighttime awakenings from hot flashes (-67%, p=0.05). There was no difference in uterine bleeding between treatment groups and placebo, and no uterine abno
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced ... Tuesday, August 4 at 11:30 a.m. Eastern Time to ... on pipeline and business progress.  Interested ... or access the webcast at www.isispharm.com .  A ... at the same address. ABOUT ISIS PHARMACEUTICALS, ...
(Date:7/28/2015)... Calif. , July 28, 2015 ... that it will report its second quarter 2015 financial ... 2015.  Rigel senior management will follow the announcement ... 4:30pm Eastern Time (1:30pm Pacific Time) to discuss ... the live conference call by dialing 855-892-1489 (domestic) ...
(Date:7/27/2015)... , July 28, 2015 CTI BioPharma ... plans to report its second quarter 2015 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 3Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results 2CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... Sept. 20 The D1,Sports Training facilities of ... proactive stance on combating bacteria with the,addition ... D1 Sport Facilities are treating the indoor ... Huntsville and Nashville facility,locations with TurfAide. Provided ...
... increases gain in height for girls with Turner ... ... 21 Novo Nordisk today,announced that Norditropin(R) (somatropin [rDNA origin] injection) ... treatment,of children with short stature associated with Turner syndrome. Turner,syndrome is ...
Cached Medicine Technology:D1 Sports Training Facilities Adopt TurfAide(TM) Antimicrobial to New Synthetic Turf Fields from AstroTurf(R) 2Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 2Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 3Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 4Norditropin(R) Approved for Treatm